论文部分内容阅读
目的评价硝苯地平与吡格列酮治疗高血压冠心病的临床疗效。方法选择484例高血压冠心病的患者,随机分为吡格列酮组、硝苯地平组和联合用药组,三组均采用常规基础降压和冠心病对症治疗,生活习惯不变,硝苯地平组:硝苯地平片30mg/d,口服;吡格列酮组:15mg/d,口服;联合用药组:加用口服硝苯地平片30mg/d和盐酸吡格列酮15mg/d。治疗6个月,比较分析治疗前后的血压控制有效率、血压降低水平、心率变化水平和心绞痛发生率等。结果三组治疗后各检测指标改善具有显著性差异,联合用药组指标变化较单用吡格列酮或硝苯地平改善更显著(P<0.01)。结论吡格列酮和硝苯地平具有降压作用,联合使用效果更好。
Objective To evaluate the clinical efficacy of nifedipine and pioglitazone in the treatment of patients with hypertensive coronary heart disease. Methods 484 patients with CHD were randomly divided into two groups: pioglitazone group, nifedipine group and combination group. All the three groups were treated with routine antihypertensive and coronary heart disease, their lifestyle was unchanged. Nifedipine group: Nifedipine tablets 30mg / d, oral; pioglitazone group: 15mg / d, orally; combination group: plus oral nifedipine tablets 30mg / d and pioglitazone hydrochloride 15mg / d. Treatment for 6 months, a comparative analysis of blood pressure control before and after treatment efficiency, blood pressure levels, changes in heart rate and angina pectoris incidence. Results There was significant difference between the three groups in the improvement of each test index. The combination group showed more significant improvement than pioglitazone or nifedipine alone (P <0.01). Conclusion Pioglitazone and nifedipine have antihypertensive effect, combined effect is better.